{"id":"NCT02612337","sponsor":"Otonomy, Inc.","briefTitle":"Study of OTO-104 in Subjects With Unilateral Meniere's Disease","officialTitle":"A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-27","primaryCompletion":"2017-07-18","completion":"2017-07-18","firstPosted":"2015-11-23","resultsPosted":"2023-01-12","lastUpdate":"2023-01-12"},"enrollment":166,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Meniere's Disease"],"interventions":[{"type":"DRUG","name":"OTO-104","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OTO-104","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.","primaryOutcome":{"measure":"The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12).","timeFrame":"Week 12 (3 months)","effectByArm":[{"arm":"OTO-104 (Full Analysis Set)","deltaMin":2.191,"sd":null},{"arm":"Placebo (Full Analysis Set)","deltaMin":2.415,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.623"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37185596"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":82},"commonTop":["Nasopharyngitis","Ear pain","Headache","Upper respiratory tract infection","Hypertension"]}}